Tags

Type your tag names separated by a space and hit enter

Ropinirole treatment for restless legs syndrome.
Expert Opin Pharmacother. 2008 Mar; 9(4):611-23.EO

Abstract

BACKGROUND

Restless legs syndrome (RLS) is a chronic neurological disorder associated with sleep disturbance.

OBJECTIVE

Prepare a drug evaluation of the non-ergot dopamine agonist ropinirole in RLS.

METHODS

Review of scientific literature on RLS, particularly focusing on treatment with ropinirole.

CONCLUSION

Ropinirole has been studied for treatment of moderate to severe primary RLS in a comprehensive clinical development program. Ropinirole significantly improved symptoms of RLS, versus placebo, in patients with primary RLS. These improvements are supported by data from individual studies and pooled analyses. Significant improvements in RLS symptoms were observed within two nights of treatment. Ropinirole also produced significant benefits on objective measures of RLS motor symptoms, such as periodic leg movements, and subjective measures of sleep. Ropinirole was generally well tolerated.

Authors+Show Affiliations

SleepMed of South Carolina, 1333 Taylor St, Suite 6B, Columbia, SC 29201, USA. rbogan@sleepmed.md

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18312162

Citation

Bogan, Richard K.. "Ropinirole Treatment for Restless Legs Syndrome." Expert Opinion On Pharmacotherapy, vol. 9, no. 4, 2008, pp. 611-23.
Bogan RK. Ropinirole treatment for restless legs syndrome. Expert Opin Pharmacother. 2008;9(4):611-23.
Bogan, R. K. (2008). Ropinirole treatment for restless legs syndrome. Expert Opinion On Pharmacotherapy, 9(4), 611-23. https://doi.org/10.1517/14656566.9.4.611
Bogan RK. Ropinirole Treatment for Restless Legs Syndrome. Expert Opin Pharmacother. 2008;9(4):611-23. PubMed PMID: 18312162.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ropinirole treatment for restless legs syndrome. A1 - Bogan,Richard K, PY - 2008/3/4/pubmed PY - 2008/3/14/medline PY - 2008/3/4/entrez SP - 611 EP - 23 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 9 IS - 4 N2 - BACKGROUND: Restless legs syndrome (RLS) is a chronic neurological disorder associated with sleep disturbance. OBJECTIVE: Prepare a drug evaluation of the non-ergot dopamine agonist ropinirole in RLS. METHODS: Review of scientific literature on RLS, particularly focusing on treatment with ropinirole. CONCLUSION: Ropinirole has been studied for treatment of moderate to severe primary RLS in a comprehensive clinical development program. Ropinirole significantly improved symptoms of RLS, versus placebo, in patients with primary RLS. These improvements are supported by data from individual studies and pooled analyses. Significant improvements in RLS symptoms were observed within two nights of treatment. Ropinirole also produced significant benefits on objective measures of RLS motor symptoms, such as periodic leg movements, and subjective measures of sleep. Ropinirole was generally well tolerated. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/18312162/Ropinirole_treatment_for_restless_legs_syndrome_ L2 - http://www.tandfonline.com/doi/full/10.1517/14656566.9.4.611 DB - PRIME DP - Unbound Medicine ER -